Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin in Relapsed or Refractory Primary Central Nervous System Lymphomas
NCT00210366Phase 2Terminated
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Nov 2004
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idarubicin in primary central nervous system lymphoma (PCNSL), sponsored by International Extranodal Lymphoma Study Group. Started Nov 2004; status: terminated.
02
Drugs
idarubicin
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00210366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210366.